Indigo Diabetes is a pioneering brand that offers innovative and high-tech solutions for accurate and affordable chronic disease management. Their mission is to improve the lives of individuals living with chronic diseases by enabling accurate continuous multi-metabolite monitoring. By leveraging nanophotonics technology, Indigo provides real-time and reliable information on metabolite levels, allowing patients and healthcare providers to make informed decisions and take proactive steps to improve health outcomes.

The company is developing a revolutionary continuous multi-metabolite monitoring (CMM®) system that eliminates the need for external devices on the body, giving patients easy access to vital information at any time. With their commitment to the best possible user experience and the highest product quality, Indigo aims to transform healthcare and enhance the quality of life for millions of people worldwide. Headquartered in Ghent, Belgium, Indigo was founded in 2016 by Danaë Delbeke and her team, utilizing their expertise in photonics technology.

The brand has gained substantial support from prestigious investors, including Fund+, Ackermans & Van Haaren, and Thuja Capital, among others. Indigo's innovative approach and partnerships with Ghent University and imec have positioned them as a leader in the field of chronic disease management. Overall, Indigo's cutting-edge technology and commitment to improving healthcare make them a trailblazer in the industry, dedicated to lighting up the lives of individuals living with chronic diseases